Pro Medicus Signs $27M – 7 year Contract with US-based Partners HealthCare

20 November 2018; Company Announcement - Pro Medicus Signs Partners HealthCare - Acrobat pdf 119k Highlights PME signs 7 year deal with Partners HealthCare in the USAInitial rollout to include Massachusetts General Hospital and Brigham and Women’s Hospital, ranked fourth and twentieth best hospitals in the USA Estimated value to PME for the initial rollout in excess of AUD $27M Scope to expand to the rest of Partners HealthCare in the future Transaction-based model with significant potential upside Two of the top four hospitals in the USA are now Visage clients  Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned US subsidiary, Visage Imaging, Inc., has signed an AUD $27 million, 7-year contract with Partners HealthCare (“Partners”), the largest health system in the state of Massachusetts and one of the largest and most respected health providers in North America.  Partners was founded in 1994 by Massachusetts General Hospital (“MGH”) and Brigham and Women's Hospital (“BWH”). Partners is a national leader in biomedical and data science research, including the MGH & BWH Center for Clinical Data Science.  The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented at Partners’ two flagship hospitals, MGH and BWH, eliminating their legacy PACS with scope to expand to other Partners network hospitals at a later date.  Dr Sam Hupert, Pro Medicus CEO, described the deal as a ‘milestone’ for Pro Medicus. “Not only is it our biggest deal to date, there is the potential for further upside within the Partners network after this initial rollout is completed. In addition, MGH and BWH are two of the most prestigious medical institutions in North America renowned for their medical research, as well as their key roles as teaching hospitals

Dr Sam Hupert | CEO on Update Open Briefing

PME CEO on FY2018 Results - Acrobat pdf 483k 16 August 2018 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest Pro Medicus Limited's Full-Year Results announcement.        

Pro Medicus Limited Full-Year Results

16 August 2018; Company Announcement - Full Year Results 2017-18 - Acrobat pdf 128k Highlights After-tax profit of $12.74 million – up 36.7% Revenue of $36.02 million – up 13.9% Underlying profit of $12.57 million – up 27.4% EBIT margins increase to 48.5% Three key contract wins Cash reserves $25.24 million – up 10.8% Final dividend of 3.5 cents per share fully franked – up 50% for the year Company remains debt-free Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a record after-tax profit of $12.74 million for the year ended 30 June 2018 – an increase of 36.7% over the previous year. Full-year revenue was $36.02 million, an increase of 13.9%. Underlying profit, excluding currency movements was $12.57 million, an increase of 27.4%. The company's cash reserves were $25.24 million at the end of the period, an increase of $2.46 million for the period. The company remains debt-free and announced a final dividend of 3.5c per share fully franked making the total dividend payout for the year 6.0c fully franked, a 50% increase on the previous year. The group’s revenue from North America increased by 18.4% and revenue from European operations by 33.2%. Australian revenue was largely in line with the previous year. During the year the company signed three key contracts. In North America, an A$18 million, seven-year contract with Yale New Haven Health, one of the leading academic institutions and a A$15 million, seven- year contract with Mercy Health for Visage Open Archive. The company also announced a five-year renewal and extension agreement with I-MED, Australia's largest diagnostic imaging provider, which will see I-MED standardise on Visage RIS across all of its practices. “This has been another very successful year for

Pro Medicus Signs Industry Defining Visage 7 Open Archive Agreement with Mercy

28 June 2018; Company Announcement - Pro Medicus Signs Industry Defining Visage 7 Open Archive Agreement with Mercy - Acrobat pdf 122k Highlights Mercy to standardise on Visage 7 Open Archive across its diagnostic imaging business Industry defining transaction Estimated value to PME in excess of AUD $15M over 7 years Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned U.S. subsidiary, Visage Imaging, Inc. has signed an AUD $15M, 7 year contract with the U.S. based Mercy health system for Visage 7 Open Archive. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 Open Archive implemented across the Mercy healthcare enterprise, which is the fifth largest Catholic health system in the U.S., spanning 4 states. “This is an industry defining deal for us,” said Dr Sam Hupert, Pro Medicus CEO. “We introduced our archive to the North American market because we saw the need for a scalable, interoperable, high performance archive which we felt was not being adequately addressed by others. This deal validates our strategy. Our customers now have the flexibility to extend the use of Visage 7 in a totally modular fashion across their enterprise.” The project will involve the migration of over 25M diagnostic imaging exams from the current Mercy archive to Visage 7 Open Archive making it one of the largest medical imaging archives in North America. Commencement of the project is scheduled for late June 2018 and is to be completed in the third quarter of FY2019. Dr Hupert continued, “In March 2017, we successfully completed the implementation of Visage 7 across all of Mercy in less than 6 months setting a new standard for an

Pro Medicus Signs 5-Year Visage RIS Deal with I-MED Radiology

1 May 2018; Company Announcement - Pro Medicus Signs 5-year Visage RIS Deal with I-MED Radiology - Acrobat pdf 259k Highlights I-MED to standardise on Visage RIS across all 200 practices I-MED’s Regional Imaging (RIL) and Queensland businesses to transition to Visage RIS over next 12 months New sites to add an additional $1.4 million in revenue per annum Contracts for existing Visage RIS sites to be extended for a further 5 years Potential for upside as I-MED continues to grow Once completed, will be one of the largest RIS installations globally Leading healthcare imaging company Pro Medicus Limited [ASX: PME] today announced it has signed a five-year agreement with I-MED Radiology Network (I-MED), that will see I-MED standardise on Visage RIS across all of its practices. I-MED, Australia's largest diagnostic imaging provider, performs over 4.6 million patient procedures annually across New South Wales, ACT, Victoria, Tasmania, Northern Territory and Queensland. As part of this agreement, I-MED will transition its Regional Imaging (RIL) and Queensland practices to Visage RIS over the next 12 months. This is expected to deliver an additional $1.4 million per annum revenue once these sites are fully implemented. In addition, I-MED will extend its existing Visage RIS contract for the Victorian, NSW and ACT operations for a further 5 years. Dr Sam Hupert, CEO of Pro Medicus said, “I-MED is the largest diagnostic imaging provider in Australia and with this deal we further cement our position as leaders in the Australian RIS market. Once completed, this will be one of the largest RIS installations in the world.” I-MED Chief Executive Steven Rubic said, “We were keen to consolidate our systems into a single, national platform that would provide us with significant cost synergies

Dr Sam Hupert | CEO Interim Results Open Briefing

PME 1H FY18 Open Briefing 14 Feb 2018 - Acrobat pdf 375k 16 February 2018 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing Pro Medicus Limited's Interim Results announcement.        

Pro Medicus Limited Interim Results

16 February 2018; Company announcement - Pro Medicus Limited Interim Results - Acrobat pdf 101k Highlights Revenue of $16.57m – up 9.0% Underlying after tax profit of $5.42m– up 33.0% Net profit (after currency) of $5.07m– up 5.7% Margins increase to 41.5% Cash reserves $22.80m Company remains debt-free Fully franked interim dividend of 2.5c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a first-half underlying (less currency) after tax profit of $5.42m, 33.0% higher than the previous corresponding period on revenue, which increased 9.0% to $16.57m. Margins increased from 38.5% to 41.5% period on period. Net profit after tax and after currency losses was $5.07m for the six months to 31 December 2017 – 5.7% higher than for the previous corresponding period. The currency loss for the period was $0.35m, as compared with a gain of $0.72m in the previous corresponding period. The company's cash reserves at 31 December 2017 were $22.80m despite a 67.2% increase in the final dividend payout, increased tax payments and greater investment in research and development during the six-month period. The company remains debt-free and announced a fully franked interim dividend of 2.5c per share. During the period, Pro Medicus continued to make strong inroads into the North American market, as evidenced by the $18m contract with Yale New Haven Health (“Yale”), one of North America’s most respected healthcare institutions, signed in November 2017. Dr Sam Hupert, Pro Medicus CEO said, “All of Pro Medicus’ key implementations remain on or ahead of schedule, and revenue from these implementations and the recently announced Yale contract will continue to flow in the months ahead.” Pro Medicus’ European business performed in line with expectations, with increased revenue from several smaller sales to

Dr Sam Hupert | CEO on Update Open Briefing

Pro Medicus Open Briefing 12 15 17 - Acrobat pdf 365k 15 December 2017 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the recent Yale New Haven Health contract signing, as well as the unveiling of Visage's artificial intelligence (AI) offerings at the recent 2017 Radiological Society of North America (RSNA) annual meeting.          

Pro Medicus Showcases AI Advances at RSNA 2017

22 November 2017; Company Announcement - Pro Medicus Showcases AI Advances at RSNA 2017 - Acrobat pdf 120k Highlights Visage unveils advances in artificial intelligence (AI) at the RSNA 2017 Machine Learning Showcase. Visage 7 - the only solution to combine both AI research and AI aided diagnostic interpretation capabilities in a single, enterprise imaging platform. Algorithms developed by Visage as well as third parties will be demonstrated. Leading health imaging company Pro Medicus Limited [ASX: PME] today announced that its wholly owned US subsidiary, Visage Imaging, Inc., will debut its artificial intelligence (AI) offerings at the Radiological Society of North America (RSNA) 2017 annual meeting (Visage Kiosk 8149M, North Hall B) as part of the inaugural RSNA Machine Learning Showcase (November 26-30, Chicago, Illinois). Significant promise and investment are driving a wide range of AI initiatives in healthcare IT particularly in the area of health imaging. The company’s vision is to utilise its R&D capability and market leading technology to deliver cutting-edge AI offerings to optimize Enterprise Imaging worldwide. Visage will showcase technology that makes Visage 7 the first and only system to combine both AI research and AI assisted diagnostic interpretation in the same Enterprise Imaging platform. “Historically, imaging platforms for research and diagnostic purposes have been totally separate,” said Malte Westerhoff PhD, Co-founder and Global CTO of Visage Imaging. Dr Westerhoff continued, “Visage’s GPU-based architecture is ideal for AI and, combined with our open APIs, will enable us to unify research and diagnostic imaging in ways not available before. This will enable AI breakthroughs to advance patient care by giving radiologists faster access to new tools that help increase productivity and improve clinical accuracy.” The company will also show algorithms working on the ultrafast

Pro Medicus Signs $18M – 7 Year Contract with Yale New Haven Health

17 November 2017; Company Announcement - Pro Medicus Signs Yale - Acrobat pdf 83k Highlights 7 year deal with Yale New Haven Health in the US. Estimated value to PME in excess of AUD $18M. Visage 7 to be implemented across Yale’s radiology departments and enterprise-wide for clinical access to imaging results. Transaction-based model with potential upside. Consolidates PME in the US academic radiology space. Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging, Inc., has signed an AUD $18 million, 7 year contract with Yale New Haven Health (“Yale”), affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale is one of the leading, most respected academic institutions in the US. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage® 7 technology implemented across all of Yale’s radiology departments and integrated to their EHR for imaging results. The implementation will span five hospitals — Bridgeport, Greenwich, Lawrence+Memorial, Westerly, and Yale New Haven hospitals, including Yale New Haven’s Children Hospital and Smilow Cancer Hospital at Yale New Haven, as well as numerous additional imaging locations across the state of Connecticut. Yale New Haven Hospital is the primary teaching hospital of the Yale School of Medicine. The first locations are scheduled to go live early in the second half of FY2018 with the remainder to be rolled out over a six month period. “This is another very significant contract for us,” said Dr Sam Hupert, Pro Medicus CEO. “Yale is one of the top academic institutions in the US and its’ medical school is renowned. Their decision further validates

PharmacySydney.com MJDHealthPharmacy.com
Go to Top